Ibrolipim
Names
Preferred IUPAC name
Diethyl ({4-[(4-bromo-2-cyanophenyl)carbamoyl]phenyl}methyl)phosphonate
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.162.319
KEGG
UNII
  • InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23) checkY
    Key: KPRTURMJVWXURQ-UHFFFAOYSA-N checkY
  • InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)
  • InChI=1S/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)
    Key: KPRTURMJVWXURQ-UHFFFAOYSA-N
  • Brc2cc(C#N)c(NC(=O)c1ccc(cc1)CP(=O)(OCC)OCC)cc2
Properties
C19H20BrN2O4P
Molar mass 451.25
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

Ibrolipim (NO-1886) is a cholesterol lowering drug from the statin family, which acts as a lipoprotein lipase activator. The discovery of the "statin" mevalonic acid synthesis inhibitors focused new attention on control of blood lipid levels as a measure to stave off heart disease. A number of compounds have been found that treat elevated lipid levels by other diverse mechanisms. The phosphonic acid derivative ibrolipim is believed to lower those levels by accelerating fatty acid oxidation.[1]

References

  1. ↑ Yin W, Tsutsumi K (2003). "Lipoprotein lipase activator NO-1886". Cardiovascular Drug Reviews. 21 (2): 133–42. doi:10.1111/j.1527-3466.2003.tb00111.x. PMID 12847564.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.